Cited by 62Ovarian function and disordersCircadian rhythm and melatoninReproductive Biology and Fertility

Melatonin and its correlation with testosterone in polycystic ovarian syndrome

Open access
Jain, Madhu, Jain, Priyanka, Haldar, Chandana, Singh, TejBali, Jain, Shuchi·2013·Journal of Human Reproductive Sciences

Abstract

CONTEXT: Polycystic ovarian syndrome (PCOS) is considered to be the most common endocrine disorder affecting women. Melatonin, a small lipophilic indoleamine, and reproductive hormones may be interrelated. Melatonin influences sex steroid production at different stages of ovarian follicular maturation as melatonin receptors have been demonstrated at multiple sites in ovary and in intrafollicular fluid. It plays role as an antioxidant and free radical scavanger which protects follicles from oxidative stress, rescuing them from atresia, leading to complete follicular maturation and ovulation. AIMS: To study the role of melatonin in PCOS and to investigate its correlation with testosterone in patients suffering from PCOS. SETTINGS AND DESIGN: A total of 50 women with PCOS (Rotterdam criteria, 2003) and 50 age and weight matched healthy controls were selected and serum melatonin estimation was done in both the groups and correlated with serum total testosterone levels. MATERIALS AND METHODS: In a case-control study, detailed history, clinical examination and hormonal evaluation [basal levels of leutinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, prolactin, insulin, total testosterone, progesterone and melatonin] were carried out in all the participants including both cases and controls. For melatonin estimation, blood samples were collected between 12:00 am and 04:00 am on day 2(nd) of menstrual cycle and analyzed by using commercially available enzyme-linked immunosorbent assay kit. STATISTICAL ANALYSIS: Student's t-test was used to compare the significant difference in mean values between cases and control groups. Chi-square test was used to test the significant association between the qualitative variables. Linear correlation coefficient and regression analysis were done to see the amount and direction of relationship between quantitative variables. RESULTS: The mean melatonin level was observed to be significantly increased in patients (63.27 ± 10.97 pg/mL) than in controls (32.51 ± 7.55 pg/mL). Melatonin was found to be raised in all the cases of PCOS (above cut-off value of ≥45 pg/mL, P < 0.001). Total testosterone level was also raised in 72% of patients. Melatonin levels were found to be positively associated with increased testosterone (P < 0.001). In regression analysis using melatonin as dependent variable and testosterone as an independent variable, the value of R2 Χ 100 (percent variation) was found to be 72.1%. CONCLUSIONS: Women with PCOS have significantly raised serum melatonin levels and hyperandrogenemia along with increased number of atretic follicles. Further studies are required to establish a definite role of melatonin in PCOS cases with disturbed hormonal milieu. This could open up the way for therapeutic role of melatonin in treatment of patients suffering from PCOS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/0974-1208.126295

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Melatonin may directly diminish testosterone production through anti-gonadal effects and alleviate insulin resistance, hyperglycemia, and dyslipidemia.

    “Melatonin may be pertinent in PCOS as it is believed to directly diminish testosterone production through its anti-gonadal effects, alongside its advantageous roles in alleviating insulin resistance, hyperglycemia, and dyslipidemia [181].”

    From Nutritional and herbal interventions for polycystic ovary syndrome (PCOS): a comprehensive review of dietary approaches, macronutrient impact, and herbal medicine in management (2025) · cites this paper as [181]

    The Discussion (page unavailable) reports that melatonin increased androgen production in the cited follicle experiments, and the Results found a positive association between serum melatonin and testosterone in PCOS patients—not a direct testosterone-lowering effect. The Results found no significant association with the fasting glucose-to-insulin ratio, and the paper does not report melatonin alleviating insulin resistance, hyperglycemia, or dyslipidemia. (LLM, conf=0.84)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 26 · Cited by 62

Research works printed but not linked: 24

  1. [1]Franks S Polycystic ovary syndrome N Engl J Med 1995 333 853 61 7651477
  2. [2]Adams J Franks S Polson DW Mason HD Abdulwahid N Tucker M Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone Lancet 1985 2 1375 9 2867389
  3. [3]Hull MG Epidemiology of infertility and polycystic ovarian disease: Endocrinological and demographic studies Gynecol Endocrinol 1987 1 235 45 3140583
  4. [5]Glueck CJ Papanna R Wang P Goldenberg N Sieve-Smith L Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome Metabolism 2003 52 908 15 12870169
  5. [6]Talbott EO Zborowskii JV Boudraux MY Do women with polycystic ovary Syndrome have an increased risk of cardiovascular disease. Review of the evidence? Minerva Ginecol 2004 56 27 39 14973408
  6. [7]Carlomagno G Nordio M Chiu TT Unfer V Contribution of myo-inositol and melatonin to human reproduction Eur J Obstet Gynecol Reprod Biol 2011 159 267 72 21835536
  7. [8]Kadva A Djahanbakhch O Monson J Di WL Silman R Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic amenorrhea J Clin Endocrinol Metab 1998 83 3653 62 9768680
  8. [9]Luboshitzky R Qupti G Ishay A Shen-Orr Z Futerman B Linn S Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome Fertil Steril 2001 76 506 10 11532473
  9. [10]Tamura H Nakamura Y Korkmaz A Manchester LC Tan DX Sugino N Melatonin and the ovary: Physiological and pathophysiological implications Fertil Steril 2009 92 328 43 18804205
  10. [11]Reiter RJ Tan DX Maldonado MD Melatonin as an antioxidant: Physiology versus pharmacology J Pineal Res 2005 39 215 6 16098101
  11. [12]Tan DX Reiter RJ Manchester LC Yan MT El-Sawi M Sainz RM Chemical and physical properties and potential mechanisms: Melatonin as a broad spectrum antioxidant and free radical scavenger Curr Top Med Chem 2002 2 181 97 11899100
  12. [13]Tan DX Manchester LC Terron MP Flores LJD Reiter RJ One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and reactive nitrogen species? J Pineal Res 2007 42 28 42 17198536
  13. [14]Itoh MT Ishizuka B Kuribayashi Y Amemiya A Sumi Y Melatonin, its precursors, and synthesizing enzyme activities in the human ovary Mol Hum Reprod 1999 5 402 8 10338362
  14. [15]Luboshitzky R Shen-Orr Z Herer P Nave R Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: The effect of ethinyl estradiol-cyproterone acetate treatment Gynecol Endocrinol 2003 17 441 7 14992162
  15. [16]Prata Lima MF Baracat EC Simões MJ Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: Similarity with polycystic ovary syndrome Braz J Med Biol Res 2004 37 987 95 15264005
  16. [17]Gonzalez F Rote NS Minium J Kirwan JP Reactive oxygen speciesinduced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome J Clin Endocrinol Metab 2006 91 336 40 16249279
  17. [18]Sabuncu T Vural H Harma M Harma M Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease Clin Biochem 2001 34 407 13 11522279
  18. [19]Gupta RK Miller KP Babus JK Flaws JA Methoxychlor inhibits growth and induces atresia of antral follicles through an oxidative stress pathway Toxicol Sci 2006 93 382 9 16807286
  19. [20]Schaeffer HJ Sirotkin AV Melatonin and serotonin regulate the release of insulin-like growth factor-I, oxytocin and progesterone by cultured human granulosa cells Exp Clin Endocrinol Diabetes 1997 105 109 12 9137942
  20. [21]Liu F Ng TB Fung MC Pineal indoles stimulate the gene expression of immunomodulating cytokines J Neural Transm 2001 108 397 405 11475007
  21. [22]Adriaens I Jacquet P Cortvrindt R Janssen K Smitz J Melatonin has dose-dependent effects on folliculogenesis, oocyte maturation capacity and steroidogenesis Toxicology 2006 228 333 43 17084011
  22. [23]Tanavde VS Maitra A In vitro modulation of steroidogenesis and gene expression by melatonin Endocr Res 2003 29 399 410 14682469
  23. [25]Woo MM Tai CJ Kang SK Nathwani PM Pang SF Leung PC Direct action of melatonin in human granulosa-luteal cells J Clin Endocrinol Metab 2001 86 4789 97 11600542
  24. [26]Tamura H Takasaki A Taketani T Tanabe M Kizuka F Lee L The role of melatonin as an antioxidant in the follicle J Ovarian Res 2012 5 5 22277103 PMC3296634

Authors
Jain, M., Jain, P., Haldar, C., Singh, T., & Jain, S.
Affiliations
Institute of Medical Sciences (IN)
Corresponding author
Jain, Madhu
Venue
Journal of Human Reproductive Sciences
Published
2013
Volume
6
Issue
4
Pages
253
ISSN
0974-1208 (ISSN-L)
OpenAlex
W1992290024
Cited by
62
References
26
Citations by year
2025: 10 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 8 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 2 · 2016: 1 · 2014: 1
FWCI
0.81
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Journal of Human Reproductive Sciences (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
Keywords
polycystic ovary syndrome, melatonin, testosterone, hyperandrogenism, follicular atresia, oxidative stress, reproductive hormones, serum melatonin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review